We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Belimumab for the treatment of pemphigus.
- Authors
Ruan, Jiali; Zhang, Xuetong; Zheng, Min
- Abstract
Here, we present the first case where the patient's PDAI score and autoantibody level decreased significantly after 4 cycles of BEL treatment, demonstrating the effectiveness of BEL. It has been hypothesized that relapses after RTX might be due to the activation of autoreactive B cells, related to the presence of high BAFF serum levels during periods of B cell depletion.8 A combined therapy associating anti-CD20 and anti-BAFF monoclonal antibodies might be of interest in pemphigus to produce more sustained B cell depletion and block return of self-reactive B cells. This case report may encourage further clinical research studies in B lymphocyte targeted therapy in patients affected by pemphigus.
- Subjects
PEMPHIGUS; AUTOIMMUNE diseases; BELIMUMAB; SYSTEMIC lupus erythematosus; B cell differentiation; PEMPHIGUS vulgaris; THERAPEUTICS
- Publication
Dermatologic Therapy, 2022, Vol 35, Issue 8, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.15621